- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT06550882
OBIZUR-tutkimus aikuisilla, joilla on hankittu hemofilia A (AHA) Etelä-Koreassa
OBIZUR-injektion [susoktokogialfa (sian antihemofiilinen tekijä VIII, rekombinantti)] markkinoille saattamisen jälkeinen seuranta (käyttötuloksen seuranta) Etelä-Koreassa hyväksyttyjen käyttöaiheiden osalta
Acquired hemophilia A (AHA) is a rare bleeding condition which prevents blood clotting. Acquired means that people are not born with this condition or have a family history of blood clotting conditions. People living with AHA can have sudden and severe bleeding. They also have longer bleeding compared to people without AHA.
The main aim of the study is to learn how safe OBIZUR is in adults with AHA.
Other aims are to see how effective OBIZUR is to control bleeding and how treatment is used in a routine clinical practice setting.
The treatment of the participants will be determined by the treating physicians.
During the study, data already existing in the participants' medical record and new data will be collected.
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
This is a prospective, and retrospective, multicenter, single-arm non-interventional post-marketing surveillance study.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Takeda Contact
- Puhelinnumero: +1-877-825-3327
- Sähköposti: medinfoUS@takeda.com
Opiskelupaikat
-
-
-
Seoul, Etelä -Korea, 06591
- Rekrytointi
- The Catholic University of Korea, Seoul St. Mary's Hospital
-
Ottaa yhteyttä:
- Site Contact
- Puhelinnumero: +82-2-2258-5745
- Sähköposti: royoon@catholic.ac.kr
-
Päätutkija:
- Jae-ho Yoon
-
Seoul, Etelä -Korea, 05278
- Rekrytointi
- Kyung Hee University Hospital at Gangdong
-
Ottaa yhteyttä:
- Site contact
- Sähköposti: pysped@khu.ac.kr
-
Päätutkija:
- Young Shil Park, Ph.D
-
Seoul, Etelä -Korea, 07804
- Rekrytointi
- Ewha Womans University Medical Center
-
Ottaa yhteyttä:
- Site Contact
- Puhelinnumero: +82-2-6986-3100
- Sähköposti: anemia@khu.ac.kr
-
Päätutkija:
- Jae-joon Han
-
Ulsan, Etelä -Korea, 44033
- Rekrytointi
- Ulsan University Hospital
-
Päätutkija:
- Yoo Jin Lee
-
Ottaa yhteyttä:
- Site Contact
- Puhelinnumero: +82-52-250-7000
- Sähköposti: yjleeh@uuh.ulsan.kr
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
Participants with AHA who are receiving OBIZUR Injection or initiate OBIZUR Injection treatment for the first time will be enrolled.
Kuvaus
Inclusion Criteria:
- Participants with AHA.
- Participants who are determined to have the clinical need to receive Obizur treatment.
- Participants aged 18 years or older at time of initiation of Obizur treatment.
- Participants agreed to participate in the study and voluntarily signed the informed consent.
Exclusion Criteria:
- Participants with hypersensitivity to any of the components of this drug.
- Participants with Congenital Hemophilia A with Inhibitors (CHAWI).
- Participants for whom Obizur treatment is contraindicated as per product label.
- Participants who has participated in another clinical study involving a medicinal product or device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving a medicinal product or device during the course of the study.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Havaintomallit: COHORT
- Aikanäkymät: OTHER
Kohortit ja interventiot
Ryhmä/Kohortti |
Interventio / Hoito |
|---|---|
|
All Participants
Participants with AHA who are receiving OBIZUR injection or initiate OBIZUR Injection treatment for the first time will be enrolled. Both retrospective and prospective participants data will be collected. Retrospective data will be collected from the date of first treatment with OBIZUR injection after the marketing authorization in Korea but before date of signed informed consent and prospective data will be collected from the date of signed informed consent. The treatment and follow up of the participants will be determined by the treating physicians according to her/his routine practice. |
OBIZUR injection.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Number of Participants With Adverse Events (AEs), Causality to AEs, Serious AEs (SAEs) and AEs of Special Interest (AESI)
Aikaikkuna: Up to 3 months
|
Number of participants with AEs, causality to AEs, SAEs and AESI will be reported. The investigator will assess the causal relationship (causality) between the medicinal product and the AE using his/her clinical expertise and judgment. |
Up to 3 months
|
|
Number of Participants With Expected/Unexpected AEs and SAEs
Aikaikkuna: Up to 3 months
|
Unexpected AE is defined as AE that differs from the information in the product label in nature, severity, specificity, or outcome. |
Up to 3 months
|
|
Number of Participants With Adverse Drug Reactions (ADRs), Unexpected ADRs, Serious ADRs, Expected SADRs and Unexpected SADRs
Aikaikkuna: Up to 3 months
|
An ADR refers to any undesirable and unintended reaction which occurs during or following the administration of the drug, and in which a causal relationship with the drug cannot be ruled out. In the event that a causal relationship with the drug remains unknown amongst reported adverse events, such reaction shall be considered an adverse drug reaction. Serious ADR means noxious or unintended response to a drug that occurs at any dosage and that requires in-patient hospitalization or prolongation of existing hospitalization, causes congenital malformation, results in persistent or significant disability or incapacity, is life-threatening or results in death. Unexpected ADRs is defined as ADR that differs from the information in the product label in nature, severity, specificity, or outcome. |
Up to 3 months
|
|
Number of Participants With Special Situation Report (SSR)
Aikaikkuna: Up to 3 months
|
SSR include following events: Pregnancy: any case in which a pregnancy participant is exposed to a Takeda Product or in which a female participant or partner of a male participant becomes pregnant following Takeda product.; Breastfeeding: infant exposure from breast milk; Overdose: all information of any accidental or intentional overdose; Drug abuse, misuse or medication error: all information on medicinal product (MP) abuse, misuse of medication error (potential or actual); Suspected transmission of infectious agent: Suspected (in sense of confirmed or potential) transmission of infectious agent by a MP; Lack of efficacy of Takeda Product; accidental/occupational exposure; Use outside the terms of the marketing authorization, also known as "off-label" and "off-label use"; Use of falsified and counterfeit MP; Drug-drug and drug-food interactions; Inadvertent or accidental exposure with or without an AE; Unintended benefit. |
Up to 3 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Percentage of Participants With Overall Bleeding Control
Aikaikkuna: Up to 3 months
|
Overall Bleeding Control will be determined as either bleeding stopped or did not stop. |
Up to 3 months
|
|
Time to Achieve Bleeding Control With OBIZUR Injection
Aikaikkuna: Up to 3 months
|
Time to achieve bleeding control will be assessed from initiation of OBIZUR Injection (start time) to the time to achieve bleeding control (stop time). |
Up to 3 months
|
|
Number of OBIZUR Injection Infusion Required to Achieve Bleeding Control
Aikaikkuna: Up to 3 months
|
Number of OBIZUR injection infusion required to achieve bleeding control will be reported. |
Up to 3 months
|
|
Dose of OBIZUR Required to Stop the Bleeding
Aikaikkuna: Up to 3 months
|
OBIZUR dose required to stop the bleeding will be reported. |
Up to 3 months
|
|
Percentage of Participants With Bleeding Events
Aikaikkuna: Up to 3 months
|
Bleeding events will be evaluated and reported as re-bleed, concurrent bleed and subsequent bleed. Re-bleed: if it occurs in the same anatomical location and within 72 hours of the resolution of the previous bleeding. Concurrent bleed: if it occurs at the same time (that is, during treatment or within 72 hours of resolution) as previous bleed but at a different anatomical location. Subsequent bleed: if it is a new bleed occurring 72 hours after the resolution of the previous bleed (either in the same anatomical location or in a new one). |
Up to 3 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojohtaja: Study Director, Takeda
Julkaisuja ja hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- TAK-672-4002
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD-jaon käyttöoikeuskriteerit
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
- MAHLA
- ICF
- CSR
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .